Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis.
about
The amelioration of cartilage degeneration by photo-crosslinked GelHA hydrogel and crizotinib encapsulated chitosan microspheres.Emerging targets in osteoarthritis therapy.Monoclonal antibodies for the treatment of osteoarthritis.Procyanidins Mitigate Osteoarthritis Pathogenesis by, at Least in Part, Suppressing Vascular Endothelial Growth Factor SignalingInflammation in joint injury and post-traumatic osteoarthritisInterleukin-1β induces fibroblast growth factor 2 expression and subsequently promotes endothelial progenitor cell angiogenesis in chondrocytes.Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Anti-vascular endothelial growth factor treatment decreases bladder pain in cyclophosphamide cystitis: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal model study.Inhibition of vascular endothelial growth factor with shRNA in chondrocytes ameliorates osteoarthritis.Vascular Endothelial Growth Factor in Cartilage Development and Osteoarthritis.Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis.Protodioscin ameliorates oxidative stress, inflammation and histology outcome in Complete Freund's adjuvant induced arthritis rats.Platelet-activated serum might have a therapeutic effect on damaged articular cartilage.Local intra‑articular injection of vascular endothelial growth factor accelerates articular cartilage degeneration in rat osteoarthritis model.Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis.Painful Understanding of VEGF
P2860
Q33728287-61EB967E-FB8F-44F6-803F-0F82D12FB373Q35752078-878AA2E9-7CF2-4DCE-8F52-129C75DD3589Q36113839-212FF307-5334-465D-AA14-443F5EE62433Q36219819-7070BF75-A93A-46CF-96E5-DBA737A9F335Q36242292-5FE3E433-1485-47B3-AAA6-2D68BC89FBF7Q36701444-1D924CFF-8AE5-41F8-A296-F03CBD5CA035Q36890872-CDC8EA43-318F-4860-A3AC-5F8C4E48434FQ38743785-C2FAF490-0C82-4720-BB9F-38A9DC687D8EQ40680223-EC2104FF-F1B1-4CC7-862D-8AAF0F0D89D1Q42375971-4E0E2BCA-7F27-459C-A087-BE0A902D49B2Q47368100-018B8C07-0BEA-42CD-8209-B63828218D64Q50060806-D1A7854C-0076-46D3-8399-110002DBF763Q51005767-4DECB441-2096-435B-85CE-D8A05C1744FBQ55312559-C3889CB9-AB88-4261-B79C-41C546FFCE13Q55439694-25EFA6E7-878D-468C-BEF0-00ED7CC6ADD5Q59128370-2D80A0C4-3398-4A80-BC32-A4B46868F8AA
P2860
Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Bevacizumab, an anti-vascular ...... body, inhibits osteoarthritis.
@en
type
label
Bevacizumab, an anti-vascular ...... body, inhibits osteoarthritis.
@en
prefLabel
Bevacizumab, an anti-vascular ...... body, inhibits osteoarthritis.
@en
P2093
P2860
P1476
Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis
@en
P2093
Joji Mochida
Miyuki Kobayashi
Munetaka Yokoyama
Toshihiro Nagai
Yoshiki Tani
P2860
P2888
P356
10.1186/S13075-014-0427-Y
P50
P577
2014-09-18T00:00:00Z
P5875
P6179
1049703115